Biomarker- and histology-driven prescribing has become standard practice in the treatment of non-small-cell lung cancer (NSCLC). The treatment algorithms for NSCLC—including those for biomarker-defined patient subpopulations—continue to evolve, driven by the approval of novel agents, often with associated biomarkers. Several underserved areas of high unmet need offer significant commercial opportunity for innovative agents. This report provides insight on how treatment options for NSCLC are likely to change over the 2015-2025 forecast period. It also analyzes the current and future earnings potential of drugs already in the market and those expected to be approved for NSCLC.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 32 country-specific interviews with key opinion leaders and 212 country-specific surveys with community oncologists treating NSCLC.
Epidemiology: Incidence by disease stage (stage IA, stage IB, stage IIIA, stage IIIB, stage IV) for adenocarcinoma, large-cell NSCLC, squamous-cell carcinoma, and other NSCLC histologies; progressed incidence of stage IV adenocarcinoma, large-cell/other NSCLC histologies, and squamous-cell NSCLC. (Note: We have applied a smoking model based on historical smoking rates when projecting the size of the future NSCLC population.)
Population segments in market forecast: For adenocarcinoma, large-cell/other NSCLC histologies, and squamous-cell/unverified histology lung cancer NSCLC: stage IB/II, stage III, metastatic first line, second line, and third line.
Emerging therapies: Phase II: 27 drugs; Phase III: 25.